Quantitative microtiter fibronectin fibrillogenesis assay: Use in high throughput screening for identification of inhibitor compounds

Matrix Biology

Volumn 31, Issue 6, 2012, Pages 360-367

  Tomasini Johansson, Bianca R ^a   Johnson, Ian A ^a   Hoffmann, F Michael ^b   Mosher, Deane F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cantharidin; Extracellular matrix; Fibrillogenesis; Fibronectin; HTS; Kinase inhibitors; Piperlongumine

Indexed keywords

1 (5 CHLORO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; APOSCOPOLAMINE; CANTHARIDIN; FIBRONECTIN; HA 100; IMATINIB; MAPROTILINE; PHOSPHOTRANSFERASE INHIBITOR; PIPERLONGUMINE; SELF ASSEMBLED MONOLAYER; TYRPHOSTIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CYTOTOXICITY; DRUG MECHANISM; FIBROBLAST; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE MICROTITER FIBRONECTIN FIBRILLOGENESIS ASSAY; SIGNAL TRANSDUCTION;

CELLS, CULTURED; FIBROBLASTS; FIBRONECTINS; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TITRIMETRY;

ALEXA;

EID: 84870061538     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2012.07.003     Document Type: Article

References (61)

1. Allen-Hoffmann B.L., Mosher D.F. Matrix assembly sites for exogenous fibronectin are decreased on human fibroblasts after treatment with agents which increase intracellular cAMP. J. Biol. Chem. 1987, 262:14361-14365.
2. Blum G., Gazit A., Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. 2003, 278:40442-40454.
3. Brunner M., Millon-Fremillon A., Chevalier G., Nakchbandi I.A., Mosher D., Block M.R., Albiges-Rizo C., Bouvard D. Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition. J. Cell Biol. 2011, 194:307-322.
4. Chen T.C., Hinton D.R., Zidovetzki R., Hofman F.M. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab. Invest. 1998, 78:165-174.
5. Chernousov M.A., Fogerty F.J., Koteliansky V.E., Mosher D.F. Role of the I-9 and III-1 modules of fibronectin in formation of an extracellular fibronectin matrix. J. Biol. Chem. 1991, 266:10851-10858.
6. Chiang H.Y., Korshunov V.A., Serour A., Shi F., Sottile J. Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1074-1079.
7. Cho J., Mosher D.F. Characterization of fibronectin assembly by platelets adherent to adsorbed laminin-111. J. Thromb. Haemost. 2006, 4:943-951.
8. Dallas S.L., Sivakumar P., Jones C.J., Chen Q., Peters D.M., Mosher D.F., Humphries M.J., Kielty C.M. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J. Biol. Chem. 2005, 280:18871-18880.
9. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., Leof E.B. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114:1308-1316.
10. Deshpande R.V., Peterson R.H., Moore M.A. Granulocyte colony-stimulating factor-induced activation of protein kinase-C in myeloid cells. J. Cell. Biochem. 1997, 66:286-296.
11. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., Michel B.A., Hauser T., Schett G., Gay S., Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007, 56:311-322.
12. Ensenberger M.G., Tomasini-Johansson B.R., Sottile J., Ozeri V., Hanski E., Mosher D.F. Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin. J. Biol. Chem. 2001, 276:35606-35613.
13. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr. Opin. Cell Biol. 1997, 9:701-706.
14. Hanski E., Jaffe J., Ozeri V. Proteins F1 and F2 of Streptococcus pyogenes. Properties of fibronectin binding. Adv. Exp. Med. Biol. 1996, 408:141-150.
15. Hayman E.G., Ruoslahti E. Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J. Cell Biol. 1979, 83:255-259.
16. Hayman E.G., Pierschbacher M.D., Ruoslahti E. Detachment of cells from culture substrate by soluble fibronectin peptides. J. Cell Biol. 1985, 100:1948-1954.
17. Iwashita M., Oka N., Ohkubo S., Saito M., Nakahata N. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A(2) receptor antagonist. Eur. J. Pharmacol. 2007, 570:38-42.
18. Kinsey R., Williamson M.R., Chaudhry S., Mellody K.T., McGovern A., Takahashi S., Shuttleworth C.A., Kielty C.M. Fibrillin-1 microfibril deposition is dependent on fibronectin assembly. J. Cell Sci. 2008, 121:2696-2704.
19. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 2000, 6:3319-3326.
20. Li W., Xie L., Chen Z., Zhu Y., Sun Y., Miao Y., Xu Z., Han X. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci. 2010, 101:1226-1233.
21. Lin W., Wang S.M., Huang T.F., Fu W.M. Differential regulation of fibronectin fibrillogenesis by protein kinases A and C. Connect. Tissue Res. 2002, 43:22-31.
22. Magnusson M.K., Mosher D.F. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1363-1370.
23. Mao Y., Schwarzbauer J.E. Stimulatory effects of a three-dimensional microenvironment on cell-mediated fibronectin fibrillogenesis. J. Cell Sci. 2005, 118:4427-4436.
24. Maurer L.M., Tomasini-Johansson B.R., Ma W., Annis D.S., Eickstaedt N.L., Ensenberger M.G., Satyshur K.A., Mosher D.F. Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes. J. Biol. Chem. 2010, 285:41087-41099.
25. McDonald J.A., Kelley D.G., Broekelmann T.J. Role of fibronectin in collagen deposition: Fab' to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix. J. Cell Biol. 1982, 92:485-492.
26. McKeown-Longo P.J., Etzler C.A. Induction of fibronectin matrix assembly in human fibrosarcoma cells by dexamethasone. J. Cell Biol. 1987, 104:601-610.
27. McKeown-Longo P.J., Mosher D.F. Binding of plasma fibronectin to cell layers of human skin fibroblasts. J. Cell Biol. 1983, 97:466-472.
28. Md Anisuzzaman A.S., Nishimune A., Yoshiki H., Uwada J., Muramatsu I. Influence of tissue integrity on pharmacological phenotypes of muscarinic acetylcholine receptors in the rat cerebral cortex. J. Pharmacol. Exp. Ther. 2011, 339:186-193.
29. Moretti F.A., Chauhan A.K., Iaconcig A., Porro F., Baralle F.E., Muro A.F. A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J. Biol. Chem. 2007, 282:28057-28062.
30. Mosher D.F., Schad P.E. Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. J. Clin. Invest. 1979, 64:781-787.
31. Mosher D.F., Schad P.E., Vann J.M. Cross-linking of collagen and fibronectin by factor XIIIa. Localization of participating glutaminyl residues to a tryptic fragment of fibronectin. J. Biol. Chem. 1980, 255:1181-1188.
32. Oh E., Pierschbacher M., Ruoslahti E. Deposition of plasma fibronectin in tissues. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3218-3221.
33. Pankov R., Momchilova A. Fluorescent labeling techniques for investigation of fibronectin fibrillogenesis (labeling fibronectin fibrillogenesis). Methods Mol. Biol. 2009, 522:261-274.
34. Pankov R., Yamada K.M. Fibronectin at a glance. J. Cell Sci. 2002, 115:3861-3863.
35. Park B.S., Son D.J., Choi W.S., Takeoka G.R., Han S.O., Kim T.W., Lee S.E. Antiplatelet activities of newly synthesized derivatives of piperlongumine. Phytother. Res. 2008, 22:1195-1199.
36. Pauwels P.J., Palmier C. Differential functional activity of 5-hydroxytryptamine receptor ligands and beta adrenergic receptor antagonists at 5-hydroxytryptamine1B receptor sites in Chinese hamster lung fibroblasts and opossum renal epithelial cells. J. Pharmacol. Exp. Ther. 1994, 270:938-945.
37. Pereira M., Rybarczyk B.J., Odrljin T.M., Hocking D.C., Sottile J., Simpson-Haidaris P.J. The incorporation of fibrinogen into extracellular matrix is dependent on active assembly of a fibronectin matrix. J. Cell Sci. 2002, 115:609-617.
38. Peters D.M., Portz L.M., Fullenwider J., Mosher D.F. Co-assembly of plasma and cellular fibronectins into fibrils in human fibroblast cultures. J. Cell Biol. 1990, 111:249-256.
39. Raj L., Ide T., Gurkar A.U., Foley M., Schenone M., Li X., Tolliday N.J., Golub T.R., Carr S.A., Shamji A.F., Stern A.M., Mandinova A., Schreiber S.L., Lee S.W. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475:231-234.
40. Sabatier L., Chen D., Fagotto-Kaufmann C., Hubmacher D., McKee M.D., Annis D.S., Mosher D.F., Reinhardt D.P. Fibrillin assembly requires fibronectin. Mol. Biol. Cell 2009, 20:846-858.
41. Saitoh M., Ishikawa T., Matsushima S., Naka M., Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J. Biol. Chem. 1987, 262:7796-7801.
42. Saoncella S., Echtermeyer F., Denhez F., Nowlen J.K., Mosher D.F., Robinson S.D., Hynes R.O., Goetinck P.F. Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2805-2810.
43. Sasaki T., Wiedemann H., Matzner M., Chu M.L., Timpl R. Expression of fibulin-2 by fibroblasts and deposition with fibronectin into a fibrillar matrix. J. Cell Sci. 1996, 109(Pt 12):2895-2904.
44. Shi F., Harman J., Fujiwara K., Sottile J. Collagen I matrix turnover is regulated by fibronectin polymerization. Am. J. Physiol. Cell Physiol. 2010, 298:C1265-C1275.
45. Singh P., Carraher C., Schwarzbauer J.E. Assembly of fibronectin extracellular matrix. Annu. Rev. Cell Dev. Biol. 2010, 26:397-419.
46. Somers C.E., Mosher D.F. Protein kinase C modulation of fibronectin matrix assembly. J. Biol. Chem. 1993, 268:22277-22280.
47. Sottile J., Hocking D.C. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol. Biol. Cell 2002, 13:3546-3559.
48. Stegmeier F., Warmuth M., Sellers W.R., Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 2010, 87:543-552.
49. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997, 340:249-258.
50. To W.S., Midwood K.S. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 2011, 4:21.
51. Tomasini-Johansson B.R., Kaufman N.R., Ensenberger M.G., Ozeri V., Hanski E., Mosher D.F. A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin. J. Biol. Chem. 2001, 276:23430-23439.
52. Tomasini-Johansson B.R., Annis D.S., Mosher D.F. The N-terminal 70-kDa fragment of fibronectin binds to cell surface fibronectin assembly sites in the absence of intact fibronectin. Matrix Biol. 2006, 25:282-293.
53. Wierzbicka-Patynowski I., Mao Y., Schwarzbauer J.E. Analysis of fibronectin matrix assembly. Curr. Protoc. Cell Biol. 2004, 10.12.1-10.12.10.
54. Xu J., Bae E., Zhang Q., Annis D.S., Erickson H.P., Mosher D.F. Display of cell surface sites for fibronectin assembly is modulated by cell adherence to (1)F3 and C-terminal modules of fibronectin. PLoS One 2009, 4:e4113.
55. Zerlauth G., Wolf G. Plasma fibronectin as a marker for cancer and other diseases. Am. J. Med. 1984, 77:685-689.
56. Zhang Q., Checovich W.J., Peters D.M., Albrecht R.M., Mosher D.F. Modulation of cell surface fibronectin assembly sites by lysophosphatidic acid. J. Cell Biol. 1994, 127:1447-1459.
57. Zhang Q., Magnusson M.K., Mosher D.F. Lysophosphatidic acid and microtubule-destabilizing agents stimulate fibronectin matrix assembly through Rho-dependent actin stress fiber formation and cell contraction. Mol. Biol. Cell 1997, 8:1415-1425.
58. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.
59. Zhang C., Peng Y., Wang F., Tan X., Liu N., Fan S., Wang D., Zhang L., Liu D., Wang T., Wang S., Zhou Y., Su Y., Cheng T., Zhuang Z., Shi C. A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma. Biomaterials 2010, 31:9535-9543.
60. Zhong C., Chrzanowska-Wodnicka M., Brown J., Shaub A., Belkin A.M., Burridge K. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J. Cell Biol. 1998, 141:539-551.
61. Zhou X., Rowe R.G., Hiraoka N., George J.P., Wirtz D., Mosher D.F., Virtanen I., Chernousov M.A., Weiss S.J. Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev. 2008, 22:1231-1243.